Want to see DE:BNN full AI Analyst Report?
BNN Stock Chart & Stats
€2.75
€0.00(0.00%)
At close: 4:00 PM EDT
€2.75
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.13 - €3.89
Previous CloseN/A
Volume3.25K
Average Volume (3M)5.54K
Market Cap
€61.61M
Enterprise Value€116.09M
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-0.05
Next Earnings
Jan 14, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding21,847,494
10 Day Avg. Volume6,931
30 Day Avg. Volume5,538
Financial Highlights & Ratios
PEG Ratio-0.69
Price to Book (P/B)25.87
Price to Sales (P/S)0.96
P/FCF Ratio-4.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)€55.10M
Bulls Say, Bears Say
Bulls Say
Industrial Biotechnology PlatformThe company operates across several industrial biotechnology applications, including food and feed, household care, detergents, and manufacturing. This breadth gives its enzyme and microorganism capabilities multiple potential commercial pathways and reduces reliance on one narrowly defined end market.
Improving Gross MarginThe improvement in gross margin indicates that the company is capturing more value from its revenue than in the prior annual periods. If maintained, better gross economics could provide a foundation for eventual operating leverage, although current losses show that the benefit has not yet reached sustainable profitability.
No TTM Total Debt ReportedReported zero total debt for the trailing twelve months limits current contractual debt obligations and may reduce direct interest pressure on cash flow. This provides some balance-sheet support relative to a heavily debt-funded structure, although historical leverage volatility means the benefit should be monitored over time.
Bears Say
Persistent Operating LossesDeeply negative operating and net margins show that the company is not yet converting its industrial biotechnology activities into sustainable earnings. Continued losses can restrict internally funded investment, increase dependence on financing, and make recovery dependent on substantial improvement in revenue quality or operating efficiency.
Negative Shareholders’ EquityNegative shareholders’ equity materially weakens the company’s financial resilience because accumulated losses have exceeded reported equity capital. This limits the capacity to absorb further setbacks, increases reliance on external funding, and leaves less balance-sheet protection for creditors and other stakeholders.
Ongoing Cash ConsumptionNegative operating and free cash flow indicate that the business is consuming cash rather than funding its operations internally. The worsening free-cash-flow trend reduces flexibility for research, commercialization, and investment, while continued burn creates an ongoing need for external capital or other funding sources.
BNN FAQ
What was B.R.A.I.N. Biotechnology Research and Information Network AG’s price range in the past 12 months?
B.R.A.I.N. Biotechnology Research and Information Network AG lowest stock price was €2.13 and its highest was €3.89 in the past 12 months.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap?
B.R.A.I.N. Biotechnology Research and Information Network AG’s market cap is €61.61M.
When is B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date?
B.R.A.I.N. Biotechnology Research and Information Network AG’s upcoming earnings report date is Jan 14, 2027 which is in 74 days.
How were B.R.A.I.N. Biotechnology Research and Information Network AG’s earnings last quarter?
B.R.A.I.N. Biotechnology Research and Information Network AG released its earnings results on Aug 27, 2026. The company reported -€0.163 earnings per share for the quarter.
Is B.R.A.I.N. Biotechnology Research and Information Network AG overvalued?
According to Wall Street analysts B.R.A.I.N. Biotechnology Research and Information Network AG’s price is currently Overvalued.
Does B.R.A.I.N. Biotechnology Research and Information Network AG pay dividends?
B.R.A.I.N. Biotechnology Research and Information Network AG does not currently pay dividends.
What is B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate?
B.R.A.I.N. Biotechnology Research and Information Network AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does B.R.A.I.N. Biotechnology Research and Information Network AG have?
B.R.A.I.N. Biotechnology Research and Information Network AG has 21,847,494 shares outstanding.
What happened to B.R.A.I.N. Biotechnology Research and Information Network AG’s price movement after its last earnings report?
B.R.A.I.N. Biotechnology Research and Information Network AG reported an EPS of -€0.163 in its last earnings report. Following the earnings report the stock price went down -1.786%.
Which hedge fund is a major shareholder of B.R.A.I.N. Biotechnology Research and Information Network AG?
Currently, no hedge funds are holding shares in DE:BNN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
B.R.A.I.N. Biotechnology Research and Information Network Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
590.52%
Trailing 12-Months
Asset Growth
―
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
B.R.A.I.N. Biotechnology Research and Information Network AG
Headquartered in Zwingenberg, Germany, and founded in 1993, BRAIN Biotech AG (renamed from B.R.A.I.N. Biotechnology Research and Information Network AG in April 2021) specializes in the discovery, development, production, and commercialization of advanced biological solutions. These include enzymes, biocatalysts, microorganisms, and naturally derived active compounds, catering to the chemical industry across Germany, the United States, France, the Netherlands, and the United Kingdom. The company operates through two distinct segments: BioScience and BioIndustrial. The BioScience division is dedicated to uncovering and developing bioactive natural ingredients, such as sugar alternatives, taste modifiers, and other nature-based active components for diverse applications in the food, animal nutrition, skincare, cosmetics, and broader chemical sectors. Concurrently, the BioIndustrial segment focuses on identifying and optimizing enzymes and biocatalysts critical for manufacturing food and beverages, medical wound care products, lubricants, as well as for starch processing and bioethanol production. This segment also engineers microorganisms to serve as functional biomass for optimizing industrial manufacturing processes, converting greenhouse gas CO2 into a valuable industrial raw material, and facilitating the extraction of precious and rare earth metals. Furthermore, BRAIN Biotech AG has established strategic alliances with AnalytiCon Discovery GmbH and Roquette to jointly develop natural sweeteners and enhanced sweet taste solutions.